Oral siRNA Delivery to Treat Colorectal Liver Metastases
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Convenient multiple dosing makes oral administration an ideal route for delivery of therapeutic siRNA. However, hostile GI environments and nonspecific biological trafficking prevent achieving appropriate bioavailability of siRNA. Here, an orally administered AuNP-siRNA-glycol chitosan-taurocholic acid nanoparticle (AR-GT NPs) was developed to selectively deliver Akt2 siRNA and treat colorectal liver metastases (CLM). AR-GT NPs are dual padlocked nonviral vectors in which the initially formed AuNP-siRNA (AR) conjugates are further encompassed by bifunctional glycol chitosan-taurocholic acid (GT) conjugates. Covering the surface of AR with GT protected the Akt2 siRNA from GI degradation, facilitated active transport through enterocytes, and enhanced selective accumulation in CLM. Our studies in CLM animal models resulted in the reduction in Akt2 production, followed by initiation of apoptosis in cancer cells after oral administration of Akt2 siRNA-loaded AR-GT. This therapeutic siRNA delivery system may be a promising approach in treating liver-associated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Recent Advances in Chitosan-Based Carriers for Gene Delivery
Cao, Y., Tan, Y. F., Wong, Y. S., Liew, M. W. J., & Venkatraman, S. (2019) · Marine Drugs · doi:10.3390/md17060381 · Cited by 361
Rai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350
“This dual-coated system, when delivered orally, reduced the expression of Akt2 proto oncogene in the liver, increased apoptosis of cancer cells, and reduced tumor size significantly more than the polyplexes made with gold NPs coated only with CS [199].”
BackgroundXu, Y., Shrestha, N., Préat, V., & Beloqui, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.006 · Cited by 214
Serrano-Sevilla, I., Artiga, Á., Mitchell, S. G., De Matteis, L., & de la Fuente, J. M. (2019) · Molecules · doi:10.3390/molecules24142570 · Cited by 148
Engineered nanoparticles for imaging and drug delivery in colorectal cancer
Pavitra, E., Dariya, B., Srivani, G., Kang, S.-M., Alam, A., Sudhir, P.-R., Kamal, M. A., Raju, G. S. R., Han, Y.-K., Lakkakula, B. V. K. S., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.017 · Cited by 102
Self-citation
Metadata
- Authors
- Kang, S. H., Revuri, V., Lee, S.-J., Cho, S., Park, I.-K., Cho, K. J., Bae, W. K., & Lee, Y.-K.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-10-13
- Volume
- 11
- Issue
- 10
- Pages
- 10417-10429
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2755954311
- Cited by
- 83
- References
- 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.